Cite
APA Citation
Motzer, R. J., Lee, C., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., Hussain, A., Vaishampayan, U. N., Graham, R., Liu, S., McCune, S., Shaheen, M., Parmar, H., Shen, Y., Whiting, S. H., & Tannir, N. M. (n.d.). lBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100097082836.0x000022